How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Architecting with portability in mind is the best way to minimize lock-in as AI pricing models evolve. Price hikes are inevitable.
On September 8, at Goldman Sachs’ Communacopia conference, OpenAI CFO Sarah Friar confirmed that the company utilized its own frontier AI models to design the Jalapeno custom inference chip. This ...
Most of us are guilty of romanticizing the past. Do you long to be the captain of a tall ship? Just as long as you don’t mind weevils in your food, vitamin deficiencies, and death from an ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results